摘要
目的探讨重组组织型纤溶酶原激活物(rt-PA)静脉溶栓治疗超早期脑梗死的安全性与有效性。方法按入选标准筛选合适患者21例进行溶栓,以相同时期非溶栓治疗的具有相同条件的患者20例为对照组,在溶栓前及溶栓后24h、21d按欧洲脑卒中神经功能缺损评分标准(ESS)进行评定,3个月时按Barthel指数进行评定。结果溶栓组疗效优于对照组(P<0·05)。溶栓组脑出血发生1例,预后仍然良好。两组患者均无死亡病例。结论rt-PA静脉溶栓治疗超早期急性脑梗死安全、有效。
Objective To study the efficacy and safety of intravenous recombinant tissue type plasminogen activator （rt-PA） on hyperacute cerebral infarction. Methods 41 patients with the supra-early acute cerebral infarction were divided into two groups： thrombolytic group （n= 21） and control group （n= 20）. They were evaluated with European Stroke Scale （ESS） and Barthel Index before and 24 h, 21 d, 90 d after treatment. Results The scores of the thrombolytic group showed more efficacious than that of the control groups （P〈0.05）. One patient suffered from cerebral hemorrhage in thrombolytic group, however his prognosis was good. There was no death in both groups. Conclusion Thrombolytic therapy with rt-PA in the hyperacute cerebral infarction shows positive effect and safety.
出处
《中国康复理论与实践》
CSCD
2007年第1期72-73,共2页
Chinese Journal of Rehabilitation Theory and Practice
